Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic...

Area of Science:

• Hepatology
• Virology
• Clinical Medicine

Background:

• Chronic hepatitis C (CHC) treatment response prediction is crucial for patient management.
• Identifying pre-treatment factors can optimize therapeutic strategies.
• PEG interferon/ribavirin (PegIFN/RBV) is a standard CHC treatment.

Purpose of the Study:

• To develop a practical algorithm for predicting treatment response in CHC patients.
• To identify pre-treatment risk factors associated with PegIFN/RBV therapy failure.
• To create a simple risk score for prospective assessment of treatment outcomes.

Main Methods:

• Retrospective analysis of 78 previously untreated CHC patients (genotype 1) receiving PegIFN/RBV.
• Comparison of 36 pre-treatment factors to identify those predicting sustained virological response (SVR).
• Calculation of a risk score (RS) based on significant predictive factors for treatment failure.

Main Results:

• Seven key factors predicting treatment failure were identified: high HCV viral load, low platelet count, elevated GGTP, low total serum protein, high glycaemia, detectable HBc IgG antibodies, and cirrhosis.
• Patients with RS 1 had a 70% likelihood of SVR, while those with RS 3 had a 23.8% response rate.
• No SVR was achieved in patients with RS >3.

Conclusions:

• A low risk score (0-2) predicts a high probability of treatment success.
• A high risk score (>3) is predictive of treatment failure in CHC patients.
• The developed model offers a simple, clinically applicable tool for pre-treatment assessment before initiating PegIFN/RBV therapy.